FTM
First Turn Management Portfolio holdings
AUM
$536M
This Quarter Return
+14.87%
1 Year Return
+36.36%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$536M
AUM Growth
+$536M
(+8.1%)
Cap. Flow
-$21.4M
Cap. Flow
% of AUM
-3.98%
Top 10 Holdings %
Top 10 Hldgs %
46.73%
Holding
42
New
7
Increased
14
Reduced
14
Closed
7
Top Buys
| 1 |
Disc Medicine
IRON
|
$15.9M |
| 2 |
Arcellx
ACLX
|
$14.2M |
| 3 |
ADMA Biologics
ADMA
|
$9.57M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$9.44M |
| 5 |
Akero Therapeutics
AKRO
|
$6.11M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$13.4M |
| 2 |
Glaukos
GKOS
|
$13.4M |
| 3 |
Exact Sciences
EXAS
|
$13M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$11.9M |
| 5 |
Vaxcyte
PCVX
|
$10.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$30.7B
| $37.5M | 7% |
372,672
-28,957
| -7% | -$2.91M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.18B
| $29.3M | 5.47% |
309,988
-125,397
| -29% | -$11.9M |
|
3
Mirum Pharmaceuticals
MIRM
$3.73B
| $26.8M | 5.01% |
527,540
+24,526
| +5% | +$1.25M |
|
4
Nuvalent
NUVL
$5.54B
| $24.5M | 4.57% |
320,798
-11,129
| -3% | -$849K |
|
5
argenx
ARGX
$43.2B
| $24.2M | 4.52% |
43,953
+2,042
| +5% | +$1.13M |
|
6
BridgeBio Pharma
BBIO
$9.56B
| $23.8M | 4.44% |
551,684
-105,015
| -16% | -$4.53M |
|
7
Ascendis Pharma
ASND
$12.1B
| $23.2M | 4.34% |
134,687
+21,409
| +19% | +$3.7M |
|
8
Xenon Pharmaceuticals
XENE
$3.03B
| $20.7M | 3.86% |
660,617
-22,834
| -3% | -$715K |
|
9
Oric Pharmaceuticals
ORIC
$1.01B
| $20.4M | 3.81% |
2,009,923
-17,507
| -0.9% | -$178K |
|
10
Natera
NTRA
$23.2B
| $20M | 3.72% |
118,130
-21,812
| -16% | -$3.68M |
|
|
11
ADMA Biologics
ADMA
$4.1B
| $19.9M | 3.71% |
1,092,361
+525,416
| +93% | +$9.57M |
|
12
Intuitive Surgical
ISRG
$168B
| $17.6M | 3.28% |
32,305
+10,196
| +46% | +$5.54M |
|
13
Insulet
PODD
$24.3B
| $16.2M | 3.01% |
51,408
+2,058
| +4% | +$647K |
|
14
TG Therapeutics
TGTX
$4.72B
| $16.1M | 3.01% |
447,884
+47,240
| +12% | +$1.7M |
|
|
15
Disc Medicine
IRON
$2.13B
| $15.9M | 2.96% |
+299,464
| New | +$15.9M |
|
16
Guardant Health
GH
$8.29B
| $15.7M | 2.93% |
302,307
-13,430
| -4% | -$699K |
|
17
Merus
MRUS
$5.01B
| $15.4M | 2.87% |
292,964
-170,996
| -37% | -$8.99M |
|
18
Revolution Medicines
RVMD
$7.39B
| $15.3M | 2.85% |
415,591
+75,482
| +22% | +$2.78M |
|
19
Axsome Therapeutics
AXSM
$6.16B
| $15.1M | 2.81% |
144,400
+26,221
| +22% | +$2.74M |
|
20
Boston Scientific
BSX
$158B
| $14.9M | 2.78% |
138,834
-39,322
| -22% | -$4.22M |
|
|
21
Arcellx
ACLX
$3.87B
| $14.2M | 2.64% |
+215,223
| New | +$14.2M |
|
22
Apogee Therapeutics
APGE
$2.26B
| $13.5M | 2.52% |
311,490
+81,815
| +36% | +$3.55M |
|
23
RadNet
RDNT
$5.41B
| $11.3M | 2.1% |
197,759
+40,144
| +25% | +$2.28M |
|
24
Janux Therapeutics
JANX
$1.37B
| $10.3M | 1.93% |
447,420
+17,257
| +4% | +$399K |
|
25
Enliven Therapeutics
ELVN
$1.24B
| $10.2M | 1.91% |
509,987
-25,105
| -5% | -$504K |
|